Yoshikane Kikushige

Yoshikane Kikushige

Auto-generated profile, based on publicly available information

Yoshikane Kikushige

Kyushu University Graduate School of Medical Science

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
TSTeppei Sakoda
Teppei Sakoda
YKYoshikane Kikushige
Yoshikane Kikushige
TMToshihiro Miyamoto
Toshihiro Miyamoto
HIHidetoshi Irifune
Hidetoshi Irifune
THTakuya Harada
Takuya Harada
KAKoichi Akashi
Koichi Akashi
The activation of β-catenin plays critical roles in normal stem cell function, and, when aberrantly activated, the maintenance and enhancement of cancer stemness in many solid cancers. Aberrant β-catenin activation is also observed in acute myeloid leukemia (AML), and crucially contributes to self-renewal and propagation of leukemic stem cells (LSCs) regardless of mutations in contrast with such solid tumors. In this study, we showed that the AML-specific autocrine loop comprised of T-cell immunoglobulin mucin-3 (TIM-3) and its ligand, galectin-9 (Gal-9), drives the canonical Wnt pathway to stimulate self-renewal and propagation of LSCs, independent of Wnt ligands. Gal-9 ligation activates the cytoplasmic Src homology 2 domain of TIM-3 to recruit hematopoietic cell kinase (HCK), a Src family kinase highly expressed in LSCs but not in HSCs, and HCK phosphorylates p120-catenin to promote formation of the LDL receptor–related protein 6 (LRP6) signalosome, hijacking the canonical Wnt pathway. This TIM-3/HCK/p120-catenin axis is principally active in immature LSCs compared with TIM-3–expressed differentiated AML blasts and exhausted T cells. These data suggest that human AML LSCs constitutively activates β-catenin via autocrine TIM-3/HCK/p120-catenin signaling, and that molecules related to this signaling axis should be critical targets for selective eradication of LSCs without impairing normal HSCs.

1 January 2020 in Journal of Clinical and Experimental Hematopathology
Verified
Journal Article
Open access
PDF file
YKYoshikane Kikushige
Yoshikane Kikushige
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries and is characterized by the clonal expansion of mature CD5+ B cells. There have been substantial advances in the field of CLL research in the last decade, including the identification of recurrent mutations, and clarification of clonal architectures, signaling molecules, and the multistep leukemogenic process, providing a comprehensive understanding of CLL pathogenesis. Furthermore, the development of therapeutic approaches, especially that of molecular target therapies against CLL, has markedly improved the standard of care for CLL. This review focuses on the recent insights made in CLL leukemogenesis and the development of novel therapeutic strategies.

22 June 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
YKYoshikane Kikushige
Yoshikane Kikushige
Acute myeloid leukemia (AML) is hierarchically organized by self‐renewing leukemic stem cells (LSCs). LSCs originate from hematopoietic stem cells (HSCs) by acquiring multistep leukemogenic events. To specifically eradicate LSCs, while keeping normal HSCs intact, the discrimination of LSCs from HSCs is important. We have identified T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM‐3) as an LSC‐specific surface molecule in human myeloid malignancies and demonstrated its essential function in maintaining the self‐renewal ability of LSCs. TIM‐3 has been intensively investigated as a “coinhibitory” or “immune checkpoint” molecule of T cells. However, little is known about its distinct function in T cells and myeloid malignancies. In this review, we discuss the structure of TIM‐3 and its function in normal blood cells and LSCs, emphasizing the specific signaling pathways involved, as well as the therapeutic applications of TIM‐3 molecules in human myeloid malignancies.

3 December 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
YKYoshikane Kikushige
Yoshikane Kikushige

15 March 2022 in JACC: Cardiooncology
Verified
Journal Article
Open access
KHKiwamu Hatakeyama
Kiwamu Hatakeyama
MHMichinari Hieda
Michinari Hieda
YSYuichiro Semba
Yuichiro Semba
SMShohei Moriyama
Shohei Moriyama
YWYuqing Wang
Yuqing Wang
YKYoshikane Kikushige
Yoshikane Kikushige

26 December 2024 in Cancer Science
Verified
Journal Article
Open access
TSTeppei Sakoda
Teppei Sakoda
YKYoshikane Kikushige
Yoshikane Kikushige
HIHidetoshi Irifune
Hidetoshi Irifune
GKGentaro Kawano
Gentaro Kawano
THTakuya Harada
Takuya Harada
KAKoichi Akashi
Koichi Akashi
In this study, we investigated the measurable residual leukemic stem cell (MR‐LSC) population after allogeneic stem cell transplantation (allo‐SCT) for high‐risk acute myeloid leukemia (AML), utilizing T‐cell immunoglobulin mucin‐3 (TIM‐3) expression as a functional marker of AML leukemic stem cells (LSCs). Analysis of the CD34+CD38− fraction of bone marrow cells immediately after achievement of engraftment revealed the presence of both TIM‐3+LSCs and TIM‐3− donor hematopoietic stem cells (HSCs) at varying ratios. Genetic analysis confirmed that TIM‐3+ cells harbored patient‐specific mutations identical to those found in AML clones, whereas TIM‐3− cells did not, indicating that TIM‐3+CD34+CD38− cells represent residual AML LSCs. In 92 allo‐SCT occasions involving 83 AML patients, we enumerated the frequencies of TIM‐3+LSCs immediately after achieving hematologic complete remission with complete donor cell chimerism. Notably, only 22.2% of patients who achieved a TIM‐3+MR‐LSClow status (<60%) experienced relapse, with a median event‐free survival (EFS) of 1581 days (median follow‐up duration was 2177 days among event‐free survivors). Conversely, 87.5% of patients with TIM‐3+MR‐LSCint/high (≥60%) relapsed, with a median EFS of 140.5 days. Furthermore, MR‐LSC status emerged as a significant independent risk factor for relapse (hazard ratio, 8.56; p < 0.0001), surpassing the impact of patient disease status prior to allo‐SCT, including failure to achieve complete remission (hazard ratio, 1.98; p = 0.048). These findings suggest that evaluating TIM‐3+ MR‐LSCs immediately after engraftment, which reflects the competitive reconstitution of residual TIM‐3+ LSCs and donor HSCs, may be valuable for predicting outcomes in AML patients undergoing allo‐SCT.